Inotrope-dependent patients may become haemodynamically unstable during treatment in the hyperbaric chamber. One possible cause is altered performance of infusion devices. We tested six Atom 235 syringe infusion pumps under hyperbaric conditions of 2.8 atmospheres absolute in a multiplace chamber using a gravimetric method. There was a small but significant reduction in infused volume during a thirty-minute period including compression time. We concluded that altered inotrope delivery may explain at least some of the haemodynamic instability sometimes seen, although a physiologic effect of hyperbaric treatment cannot be excluded.
Infusion devices are used in the hyperbaric chamber for purposes such as the accurate titrated delivery of inotropic agents and sedatives in critically ill patients. Anecdotal evidence from this institution and others indicates that patients requiring inotropic support may experience haemodynamic instability particularly during the compression phase of hyperbaric treatment 1 . This may be due to a physiologic effect and/or a malfunction of the inotrope delivery system.
In monoplace hyperbaric chambers the infusion pump is used outside the chamber and must pump fluid to the patient against the ambient-to-chamber pressure gradient. It has been proposed that this pressure gradient may lead to malfunction of infusion devices 2 . However, in multiplace hyperbaric chambers, the infusion device used is inside the chamber and has no pressure gradient to overcome. Increased pressure and fire prevention requirements place constraints upon the suitability of medical equipment for use in hyperbaric chambers. Whilst there are general guidelines for equipment to be used in hyperbaric chambers, to our knowledge there has been no systematic investigation of infusion device function in a multiplace hyperbaric chamber. We proposed to examine the performance of the Atom 235 syringe infusion pump (Atom Medical Corporation, Tokyo) in our multiplace chamber. Our hypothesis was that pump performance under hyperbaric compression would differ from control normobaric conditions.
MATERIALS AND METHODS
We studied six Atom 235 pumps which had previously had long-life batteries installed by our hospital biomedical engineers to allow adequate duration of function during hyperbaric chamber operations. For each study a 50 ml Luer Lock syringe (Terumo Medical Corporation, Elkton, MD) was filled with 30 ml of 0.9% saline. To ensure the elimination of all air bubbles, the syringes were filled inverted and adherent bubbles were dislodged with tapping. Terumo was one of the syringe brands approved for use with the Atom 235 infusion pump. The syringe was connected via 1 ml/140 cm low deadspace tubing (Braun, Malaysia) to a 16 gauge intravenous cannula. This assembly was then placed in one of the Atom 235 pumps and primed according to the manufacturer's instructions. The pump and assembly were then placed in the multiplace hyperbaric chamber (altitude: 16m above sea level) with the tip of the intravenous cannula suspended over the centre of a 10 ml measuring cylinder at a height approximating the centre of the 50 ml syringe as it sat in the pump.
The study consisted of three consecutive thirtyminute phases: 1. normobaric with the chamber door open "pre"; 2. compression to 2.8 atmospheres absolute (ATA) at 0.1 ATA/min for 18 minutes followed by 12 minutes at 2.8 ATA "compression"; 3. normobaric with the door open "post". The study was performed with one investigator in the chamber while another operated the external chamber controls. All chamber operations were conducted within the Canadian Defence and Civil Institute of Environmental Medicine (DCIEM) sport diving tables 3 to minimize the risk of decompression illness to the investigator in the chamber.
The pumps and assemblies were not moved between the phases, nor were the syringes refilled although the measuring cylinders were emptied and dried. During each phase the pumps were programmed to infuse into the measuring cylinders at 10 ml/hr for 30 minutes timed by an electronic timer outside the chamber. The expected pump infusion volume was thus 5.0 ml per phase. To minimize the electrical fire risk and potential weighing balance errors, measuring cylinders were weighed on an electronic balance (Sartorius L 2200 P, Göttingen, Germany) outside the chamber. The cylinders were weighed at the beginning and end of each phase, with the difference being used as the mass of saline infused. This was converted to a volume using physical chemistry tables 4 .
The hypothesis that the pump delivery rate during hyperbaric compression would differ from normobaric was tested using the Wilcoxon signed rank test. A further comparison was made between the precompression and post-compression normobaric phases. A P value of less than 0.05 (P<0.05) was regarded as significant with allowance made for two comparisons. The 95% confidence intervals (CI) for the median changes were calculated. Minitab statistical software (Minitab, PA, U.S.A.) was used.
RESULTS
These are shown in Table 1 . There was a significant decrease in the volume infused between the precompression and compression phases (P<0.05) with a median decrease of 0.4 ml (CI 0.025-0.565 ml). Further there was a significant increase in volume infused between the pre-compression and postcompression phases (P<0.05) with median increase of 0.17 ml (CI 0.12-0.48). During all phases of the study the volume infused was less than the predicted value of 5.0 ml. These results concur with results of a volumetric pilot study (unpublished results).
DISCUSSION
The ideal attributes of an infusion device for use in a multiplace hyperbaric chamber might include: small robust construction, battery power lasting for several hours, nonflammable lubrication, electrical and fire safety under pressure and reliable performance across all phases of compression and decompression. This study indicates that the Atom 235 syringe pump performance is not uniform during compression to and from a pressure of 2.8 ATA (which is frequently used in hyperbaric treatment).
One widely accepted technique for testing the accuracy of infusion devices is a computerized gravimetric method 5 . Unfortunately the equipment for computerized gravimetric measurement requires mains AC electrical power which is unsafe for use in hyperbaric chambers. We took several steps to improve the accuracy of the non-computerized gravimetric method used in this study. First, the infusion rate of 10 ml/hr was above the minimum of 5 ml/hr recommended by the Australian Therapeutic Goods Administration 6 for this type of pump. Second, we used an infusion time of 30 minutes to overcome the brief fluctuations in infusion rate seen previously with the Atom 235 7 .
The finding of a decreased infused volume after compression followed by an increased infused volume after decompression suggested the effects of a nonequilibrated gas space in the system. This was supported by the incidental observation during pilot studies that in two of the pumps during actual compression to 2.8 ATA, fluid in the low deadspace tubing was seen to draw back into the tubing. The site of the proposed gas space was unclear, however the space between the sealing rings of the rubber cap of the syringe plunger was one possibility.
Review of the literature revealed two possible explanations for the finding that the infused volumes for all phases were less than expected. The first is "backlash" 5 which is due to delayed engagement of the drive system, although in this study priming the system prior to use as according to the manufacturer's instructions should have avoided this problem. The second is the "breakfree" force 7 required to overcome the resistive forces of the syringe. This seemed to be the more likely explanation in this study. Further the resistive forces of the syringe may have varied with the changing volume of the gas trapped between the sealing rings of the syringe.
Our study suggested that the compression phase is the time of greatest variation in infusion pump delivery rate. This finding correlates with the observation that the compression phase of treatment is the time of greatest instability in inotrope-dependent patients undergoing hyperbaric therapy 1 . The average reduction in infused volume during the compression phase was 7% of the pre-compression value. Although this is a small change, to our knowledge there are no clear dose-response curves for inotropes and vasoconstrictors in critically ill patients. It is possible that some unstable critically ill patients may be very sensitive to minor changes in inotrope/vasoconstrictor infusion rates. The compression rate most frequently used therapeutically is approximately twice that used in this study and it is possible that greater changes in pump infusion rate may be seen with more rapid rates of pressurization. We used a compression rate at the slower end of clinically used compression rates to allow the pumps to be exposed to changing ambient pressure for a longer time period.
Evans and Weaver 2 have suggested that infusion pumps used by hyperbaric units should be individually calibrated for different pressures. Even this might not overcome problems related to inconsistent pump performance during dynamic compression.
To minimize the risk of critical incidents for inotrope-dependent patients receiving hyperbaric treatment requires awareness of the potential for haemodynamic instability, accurate continuous haemodynamic monitoring and a preparedness to rapidly titrate inotropes to physiologic endpoints. Knowledge of the nature and extent of the changes in function of particular infusion devices when used under pressure would allow anticipation of likely setting changes required for these devices.
In summary we demonstrated changes in performance of the Atom 235 syringe infusion pump during and after hyperbaric compression to 2.8 ATA. This finding suggests at least some equipment basis for haemodynamic instability in inotrope-dependent patients during hyperbaric treatment but does not exclude a physiologic effect of compression or hyperbaric oxygen. Further, the changes in infusion pump performance during hyperbaric chamber operations cannot be reliably predicted. Therefore, in institutions where infusion devices are used under hyperbaric conditions, all infusion devices should be calibrated in the conditions under which they will be used.
